Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Targeted antibiotic safe and effective for irritable bowel syndrome

Among the most commonly used treatments for irritable bowel syndrome - which affects as many as 20 percent of the United States population - a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.

2 Nov 2011

Vampire-like bacteria has potential to serve as living antibiotic

A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.

1 Nov 2011

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Viewpoints: Judd Gregg on revamping entitlements and taxes; John Breaux on slashing Medicare fraud; Medicaid limits on hospital stays

Consider this. As of this year, every other household in America will have at least one person in it who is receiving an entitlement benefit, according to the Census Bureau. As of this year, fewer than half of the Americans who have earned income will pay income taxes on that income.

1 Nov 2011

Panel backs anthrax vaccine testing on children

An important panel of government advisers Friday recommended that the government should sponsor a controversial study to test the anthrax vaccine in children to see whether the inoculation would protect young Americans against a bioterrorist's attack.

31 Oct 2011

Nursing home residence may allow for 'on-admission' prediction model of C. difficile infection severity

Antibiotics may not be the only risk factor associated with community-acquired Clostridium difficile infection, indicating that other undefined causes of the potentially life-threatening infection may exist and could also predict whether or not a patient will require hospitalization, according to the results of the study, "Predictors of Hospitalization in Community-Acquired Clostridium difficile Infection."

31 Oct 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

Researcher's compound disables bacteria instead of killing them

After 70 years, antibiotics are still the primary treatment for halting the spread of bacterial infections. But the prevalence of antibiotic resistance is now outpacing the rate of new drug discovery and approval. A microbiologist at the University of Wisconsin-Milwaukee (UWM) has discovered a different approach: Instead of killing the bacteria, why not disarm them, quashing disease without the worry of antibiotic resistance?

29 Oct 2011

American College of Gastroenterology to hold special briefing for journalists

The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.

28 Oct 2011

New discoveries on drug resistance in Leishmania

Two remarkable discoveries were today revealed by researchers into genome analysis of Leishmania parasites. These results uncovered a surprising level of variation at the genome structure level.

28 Oct 2011

NK cells can fight against anthrax

One of the things that makes inhalational anthrax so worrisome for biodefense experts is how quickly a relatively small number of inhaled anthrax spores can turn into a lethal infection. By the time an anthrax victim realizes he or she has something worse than the flu and seeks treatment, it's often too late; even the most powerful antibiotics may be no help against the spreading bacteria and the potent toxins they generate.

28 Oct 2011

New MRSA strains are not directly descended from old ones: Study

Check into a hospital and you run the risk of infection with a methicillin-resistant strain of the bacterium Staphylococcus aureus, or MRSA. But present day MRSA might have been worse if it had descended directly from a 1950s version of the bug, according to a study co-authored by Barry N. Kreiswirth, PhD, a professor at the Public Health Research Institute of UMDNJ-New Jersey Medical School, and published in the Proceedings of the National Academy of Sciences.

27 Oct 2011

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.

27 Oct 2011

Drug-resistant infections may not contribute to higher surgical ICU death rates

The rates of antibiotic-resistant infections in the intensive care unit (ICU) have increased over the last decade. But new research from the University of Virginia suggests that surgical ICU death rates may, in fact, be declining and that drug-resistant infections are not likely to be a significant factor in overall mortality rates.

27 Oct 2011

Blood tests and cultures may not be necessary in detecting early-onset GBS in newborns

For newborn infants at risk of infection with group B streptococcal (GBS) bacteria, screening blood tests cause extra pain and anxiety—without increasing detection of early-onset GBS disease, reports a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

24 Oct 2011

Intestinal ecosystem more dynamic than previously thought

The intestinal ecosystem is even more dynamic than previously thought, according to two studies by UT Southwestern Medical Center researchers published in the latest issue of Science.

20 Oct 2011

HMS launches Initiative in Systems Pharmacology

Taking aim at the alarming slowdown in the development of new and lifesaving drugs, Harvard Medical School is launching an Initiative in Systems Pharmacology, a comprehensive strategy to transform drug discovery by convening biologists, chemists, pharmacologists, physicists, computer scientists and clinicians to explore together how drugs work in complex systems.

18 Oct 2011

Action Medical Research announces grants to investigate conditions affecting babies, children

Action Medical Research - the leading UK-wide medical research charity dedicated to helping babies and children - has today announced grants worth more than £1.3 million for top researchers across the country.

13 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011